secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wellgistics Health, Inc. (WGRX)
CIK:        0002030763
Form:       8-K
Filed at:   2026-03-09T23:59:59+00:00
Accession:  0001493152-26-009384
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Wellgistics launches medical food Forzet for GLP-1 muscle loss targeting $70B market
--------------------------------------------------------------------------------

- Forzet is a medical food for dietary management of muscle loss during weight loss therapies, aimed at GLP-1 drug users.
- GLP-1 agonist market forecast to grow from $70B (2025) to $201B (2030) per Grandview Research.
- Forzet has been evaluated in multiple controlled clinical studies (Type 2 diabetes, heart failure, COPD) in Europe.
- Product is classified as medical food, not FDA-approved drug; available OTC under physician supervision.
- Initial availability through Wellgistics affiliated pharmacy and select network pharmacies; no revenue guidance provided.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2030763/000149315226009384/0001493152-26-009384-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2030763/000149315226009384/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-009384

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer